依达拉奉联合氯吡格雷治疗急性脑梗死的临床疗效观察

摘要

目的：观察分析依达拉奉联合氯吡格雷治疗急性脑梗死的临床疗效。方法：选取2015年1月至2016年1月我院收治的80例急性脑梗死病例作为观察对象，遵循双色球随机分组原则分为观察组(n=40)和对照组(n=40)，对照组采用常规治疗，观察组采用依达拉奉联合氯吡格雷治疗，观察临床疗效、不良反应、神经功能缺损评分(NIHSS)以及日常生活能力评分(ability of daily life，ADL)。结果：观察组总有效率85.00%(34/40)，高于对照组65.00%(26/40)，组间比较(P0.05)；两组患者治疗前NIHSS评分、ADL评分比较(P>0.05)；治疗后7d、14d、21d两组NIHSS评分比较(P0.05)，治疗14d、21d两组患者ADL评分比较(P0.05); The NIHSS score, ADL score of two groups of patients before treatment were compared (P>0.05); The NIHSS score after the treatment for 7d, 14d, 21d of two groups were compared (P0.05), and the ADL score after the treatment for 14d and 21d of two groups were compared (P<0.05).Conclusion: The clopidogrel combined with edaravone in treatment of acute cerebral infarction can achieve ideal treatment effect. It is beneficial to improve the neurological function defect of patients, improve the ability of daily life, and reduce adverse reaction, thus it is worthy to be promoted in the clinics.